[Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis].
Systemic chemotherapy based on 5-fluorouracil (5-FU) is a standard treatment for unresectable or recurrent large intestinal cancer. Although hyperammonemia is a known side effect of 5-FU that can cause serious pathological conditions, only a few cases have been reported. We describe 4 cases of 5-FU-related hyperammonemia with impairment of consciousness in patients who received 5-FU chemotherapy for large intestinal cancer with multiple liver metastases. Hemodialysis was effective in 1 severe case. There have been no detailed reports on the use of hemodialysis for hyperammonemia caused by 5-FU. Renal dysfunction is considered to be a risk factor for hyperammonemia caused by 5-FU and it is necessary to pay particular attention in patients with renal dysfunction who receive chemotherapy with 5-FU. Here we summarize our cases together with 16 previously reported cases of hyperammonemia caused by 5-FU in Japan.
Department of Gastroenterology, Muroran City General Hospital.
Tomoya
T
Iida
Kohei
K
Wagatsuma
Motohiro
M
Tani
Hajime
H
Sasaki
Yumiko
Y
Naganawa
Hiroyuki
H
Isshiki
Kayo
K
Murakami
Shuji
S
Satoh
Haruo
H
Shimizu
Hiroyuki
H
Kaneto
D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D005472:Fluorouracil / Q000009:adverse effects*; D006801:Humans; D022124:Hyperammonemia / Q000139:chemically induced* / Q000628:therapy; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D007420:Intestine, Large; D008113:Liver Neoplasms / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil